Last reviewed 2026-04-19 · How we verify

NK012 and 5-FU

Nippon Kayaku Co., Ltd. · Phase 1 active Small molecule

NK012 and 5-FU is a Small molecule drug developed by Nippon Kayaku Co., Ltd.. It is currently in Phase 1 development.

At a glance

Generic name	NK012 and 5-FU
Sponsor	Nippon Kayaku Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NK012 and 5-FU CI brief — competitive landscape report
NK012 and 5-FU updates RSS · CI watch RSS
Nippon Kayaku Co., Ltd. portfolio CI

Frequently asked questions about NK012 and 5-FU

What is NK012 and 5-FU?

NK012 and 5-FU is a Small molecule drug developed by Nippon Kayaku Co., Ltd..

Who makes NK012 and 5-FU?

NK012 and 5-FU is developed by Nippon Kayaku Co., Ltd. (see full Nippon Kayaku Co., Ltd. pipeline at /company/nippon-kayaku-co-ltd).

What development phase is NK012 and 5-FU in?

NK012 and 5-FU is in Phase 1.

Manufacturer: Nippon Kayaku Co., Ltd. — full pipeline
Compare: NK012 and 5-FU vs similar drugs
Pricing: NK012 and 5-FU cost, discount & access